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Background. Social phobia, also known as social anxiety
disorder, is a highly prevalent disorder with significant
morbidity. Patients with social phobia frequently develop
co-morbid psychiatric disorders such as depression and
substance abuse, and the disorder impacts significantly on
social and occupational functioning. It has been suggested
that the selective serotonin reuptake inhibitors (SSRIs) are
useful in the management of this disorder, but few controlled
trials have been undertaken in this regard. There are also few
data on the pharmacotherapy of social phobia in South Africa.
Methods. A double-blind randomised placebo-controlled
multi-site flexible-dose trial of paroxetine was undertaken
over 12 weekS among patients with a primary diagnosis of
social phobia. Primary response measures were the Glob;U
Improvement item on the Clinical Global Impression scale
(CGI) and mean change from baseline in the patient-rated
Liebowitz Social Anxiety Scale (LSAS) total score. Ninety-
three patients participated at 9 South African sites; their data
are reported here. -
Results. There was a significant drug effect on both the CGI
Global Improvement score and the LSAS at 12 weeks. In
addition, there was no significant difference in overall rate of
adverse experiences between those on paroxetine and those
on placebo.
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Conclusions. Paroxetine is both effective and safe'in the acute
treatment of social phobia. The findings here are consistent
with those of previous controlled studies of the SSRIs as well
as with previous work done in the USA on the use of
paroxetine in the treatment of this disorder. Early diagnosis
and treatment of social phobia should be encouraged.
However, further research on long-term pharmacotherapy of
social phobia is needed.
5 AIr Med J1999; 89: 402406.
Social phobia, also known as social anxiety disorder, has
increasingly been recognised as a highly prevalent diso~der
that is accompanied by significant morbidity. A recent flational
study found that lifetime prevalence of soci3I phobia r~ged
from 0.5% to 2.6%,1 although some studies have found r~tes of
social phobia to be as high as 13.3%.2 Social phobia is a chronic
and serious disorder - patients frequently develop co-morbid
psychiatric disorders such as depression and substance abuse,'
and social anxiety symptoms impact significantly on social and
occupational functioning.'
Unfortunately, social phobia remains poorly recognised and
inadequately treated in the primary care setting.' The
characteristic fear of social and performance situations where
exposure to unfamiliar people or to scrutiny occurs' may not be
recognised as representing a psychiatric disorder by either the
patient or the clinician. Nevertheless, there is growing evidence
that specific pharmacotherapeutic and psychotherapeutic
interventions can treat social phobia effectively.'
The first medications shown to be effective in controlled
trials of social phobia were the irreversible monoamine oxidase
inhibitors (MAOls).' Dietary and other restrictions necessitated
by these medications have led to interest in the more recently
introduced reversible MAOls, although evidence for the
efficacy of these agents in the management of social phobia has
been conflicting.9-12 High-potency benzodiazepines also appear
to be effective in managing social phobia,13,14 but the
dependency potential of these agents is worrisome.
Preliminary evidence of serotonergic involvement in social
phobia" provides some theoretical justification for using the
selective serotonin reuptake inhibitors (SSRIs)Y Indeed, a range
of uncontrolled trials have suggested that these agents are
useful in the treatment of social phobia.'6-" Nevertheless, there
are relatively few controlled trials of the SSRIs in this regard,
While fluvoxamine25 and sertraline26 were found to be more
effective than placebo in the acute treatment of this disorder,
sample sizes in these two studies were small (N = 30 in the
fluvoxamine study and N = 12 in the sertraline study).
Two double-blind randomised placeb<r-controlled multi-
centre trials of paroxetine in patients with a primary diagnosis
of social phobia have recently been completed, one in North
c
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America and one in Europe and South Africa.27 In this paper we
.report on the findings for the South African sites that
participated in the latter study. Given the universally high
prevalence of this disorder, its underdiagnosis in primary care
settings, and the lack of previous research in South Africa, we
concluded that publication of these data might help to raise
awareness of social phobia and its available treatment options.
METHODS
Sites and subjects
Thirty-nine sites, located in Belgium, France, Germany, Ireland,
South Africa, Spain and the UK, participated in the trial. There
were 9 sites in South Africa; 3 in State medical schools and 6 in
private practitioner settings. Investigators were chosen for their
interest in the study and their ability to enter eligible patients.
All investigators met to ensure consistent study procedures;
they also received intensive training in diagnosing social
phobia using the Mini International Neuropsychiatric
Interview (MINI).2B
Two hundred and ninety adult outpatients were enrolled in
the study, of whom 93 were from South Africa. (Demographic
details are supplied in the Results section.) All subjects met
Diagnostic and Statistical Manual (DSM-IV)6 criteria for social
phobia. Subjects had to be at least 18 years of age, and subjects
over 65 had to be able to tolerate a paroxetine starting dose of
20 mg daily and to be without renal or hepatic impairment (test
results had to be within twice the upper limit of normal). All
subjects gave written informed consent after approval of the
protocol by an ethics committee.
Patients were excluded on a number of grounds, including:
(i) co-morbid psychiatric conditions - i.e. if they had Axis I
disorders such as major depression, dysthymia, simple phobia,
obsessive-compulsive disorder, panic disorder as a primary
disorder in the past 6 months, or body dysmorphic disorder; if
there was a history of schizophrenia or bipolar disorder; if they
met DSM-IV criteria for substance abuse in the 3 months before
the trial or substance dependence in the 6 months preceding
the· trial; or if they posed a current, serious suicidal or
homicidal risk in the investigator's judgment; (ii) co-morbid
medical conditions - i.e. if there were any serious medical
disorders or conditions that would preclude paroxetine
administration; if there was a history of seizure disorder
(except for febrile seizures in childhood); if they had clinically
significant abnorrnallaboratory or electrocardiographic
findings at baseline; or if they were of child-bearing potential
and had a positive pregnancy test or were lactating or were not
practising a clinically accepted method of contraception; (iii)
treatment requirements and history - i.e. if they required
concomitant therapy from psychoactive medications other than
chloral hydrate; if they were receiving psychotherapy (except
stabilised psychotherapy regimens that were ongoing for at
least 6 months); if they had had previous treatment for social
phobia with SSRIs at a dose and for a duration that would have
been adequate to show a response (equivalent to 3 months'
treatment with fluoxetine 20 - 40 mg); if they had taken
psychoactive drugs within 14 days of baseline or depot
neuroleptics within 12 weeks of baseline; if they had used an
investigational drug within the past month (or 5 half-lives,
whichever was the longest); if they had received
electroconvulsive therapy within 3 months of entry into the
study; or if they were previously unresponsive or intolerant to
paroxetine.
Visits and medication
At the screening visit, which included a full medical and
psychiatric history and physical evaluation, patients were
assessed for eligibility to participate in the study. Thereafter,
patients underwent a 1-week single-blind placebo run-in.
Patients who scored 1 (very much improved) or 2 (much
improved) on the Global Improvement item of the Clinical
Global Impression (CGI)" scale at the subsequent (baseline)
visit were excluded.
At the baseline visit patients were randomised by computer-
generated code to paroxetine or placebo for 12 weeks. Clinic
visits then took place at weeks 1, 2, 3, 4, 6, 8 and 12 for
assessments of efficacy, safety, concomitant medications and
general compliance with study procedures. A telephonic
consultation took place at week 10 to assess safety, concomitant
medications and general compliance. Visits to each investigator
site were undertaken in order to monitor investigator
adherence to protocol.
Paroxetine and placebo were provided as identical capsules.
Paroxetine was initiated at a dosage of 20 mg daily for 2 weeks,
after which the clinician could titrate it upwards by
10 mg each week to a maximum of 50 mg daily, according to
clinical response and tolerability. One 10 mg dose reduction
was also allowed in response to adverse events. Paroxetine was
tapered over 3 weeks at the end of the 12-week study. Patients
were instructed to return medication packs with any unused
drug to the investigator at each visit, and a record of supplies
dispensed, taken, and returried was made at each visit.
A patient could withdraw or be withdrawn from the study
prematurely for the following reasons: (i) adverse experience;
(ii) ineffectiveness of treatment (patient's perception); (iii)
protocol deviation, including non-compliance; and (iv) lost to
follow-up.
Efficacy and safety
The CGI scale was administered by the treating clinician at
baseline and at each subsequent clinic visit. The Liebowitz
Social Anxiety Scale (LSAS),30 the Social Avoidance and Distress
Scale (SADS),'l and the Sheehan Disability Scale (SDS)32 were
completed by the patient at baseline and at each subsequent
clinic visi t.
